Search all ERS
Interstitial Lung Diseases
Respiratory Critical Care
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
ERJ Open Research
European Lung White Book
All ERS guidelines
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?
Mohsen Sadatsafavi, James McCormack, John Petkau, Larry D. Lynd, Tae Yoon Lee, Don D. Sin
Eur Respir J, 57 (2) 2002122; 10.1183/13993003.02122-2020
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Mohsen Sadatsafavi, James McCormack, John Petkau, Larry D. Lynd, Tae Yoon Lee, Don D. Sin. Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?. Eur Respir J, 57 (2) 2002122; 10.1183/13993003.02122-2020
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
No comment yet.
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations?
Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019
Can antibiotics prevent acute COPD exacerbation? A systematic review and meta-analysis
Source: Annual Congress 2013 –COPD: acute exacerbations and others
One year experience with acute COPD assessment service (ACAS) for patients with acute exacerbations of COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 178s
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Can we personalize COPD treatment by exacerbation frequency and severity? Three years of follow-up
Source: International Congress 2016 – In-patient and out-patient COPD management
Does having previous sputum results improve rationalisation of antimicrobial prescribing during acute exacerbations of COPD?
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Under reporting acute exacerbation in patient with COPD: incidence and predictors?
Source: Eur Respir J 2006; 28: Suppl. 50, 175s
Analysis of the frequency of COPD exacerbations in the ’real-life’ DACCORD study over a 2 year period
Source: International Congress 2016 – Comorbidities and exacerbations in COPD
COPD in the time of COVID-19: an analysis of acute exacerbations and reported behavioural changes in patients with COPD
Source: ERJ Open Res, 7 (1) 00718-2020; 10.1183/23120541.00718-2020
A global survey conducted to determine frequency of exacerbations in COPD patients
Source: Annual Congress 2013 –COPD treatment
Three practical case studies on COPD using a remote voting system: 2. At hospital: NIV for acute exacerbation of COPD
Source: Annual Congress 2013 –Management of COPD with NIV
Sit-to-stand ability in patients hospitalised for acute exacerbation of COPD: Clinical characteristics and short-term outcomes
Source: International Congress 2015 – New insights into exercise and muscle performance
Difficulty in management of COPD exacerbation: Is this chronic exacerbation or difficult COPD: “A specific phenotype?”
Source: Annual Congress 2013 –COPD biomarkers
Should we use early NIV in the ward for COPD exacerbations?
Source: International Congress 2016 – Yernault Lecture preceded by the symposium “Latest developments in noninvasive ventilation: improvements and gadgets”
Early discharge for patients with exacerbations of COPD - a real life cohort study
Source: Annual Congress 2005 - COPD - acute exacerbations
COPD exacerbation phenotypes in a five year hospitalisation cohort
Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD?
Does past experience predict future exacerbations in adults with asthma?
Source: Annual Congress 2010 - Therapy and health economics of asthma and COPD
Does influenza vaccination increase consultations for corticosteroid prescriptions or exacerbations of asthma or chronic obstructive pulmonary disease?
Source: Annual Congress 2003 - COPD: risk factors and course of disease
Systematic review: Does antibiotic treatment duration affect the outcomes of asthma and COPD exacerbations?
Source: International Congress 2017 – COPD: microbiome composition and the role of antibiotics
May the value of FEV1 be helpful in the choice of the antibiotic therapy in acute exacerbation of COPD?
Source: Eur Respir J 2001; 18: Suppl. 33, 189s